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Background: Myocardial infarction (MI) reperfusion therapy causes paradoxical cardiac
complications. Following restoration of blood flow to infarcted regions, a multitude of
inflammatory cells are recruited to the site of injury for tissue repair. Continual progression
of cardiac inflammatory responses does, however, lead to adverse cardiac remodeling,
inevitably causing heart failure.
Main Body: Increasing evidence of the cardioprotective effects of both invasive
and non-invasive vagal nerve stimulation (VNS) suggests that these may be feasible
methods to treat myocardial ischemia/reperfusion injury via anti-inflammatory regulation.
The mechanisms through which auricular VNS controls inflammation are yet to be
explored. In this review, we discuss the potential of autonomic nervous system
modulation, particularly via the parasympathetic branch, in ameliorating MI. Novel
insights are provided about the activation of the cholinergic anti-inflammatory pathway
on cardiac macrophages. Acetylcholine binding to the α7 nicotinic acetylcholine
receptor (α7nAChR) expressed on macrophages polarizes the pro-inflammatory into
anti-inflammatory subtypes. Activation of the α7nAChR stimulates the signal transducer
and activator of transcription 3 (STAT3) signaling pathway. This inhibits the secretion
of pro-inflammatory cytokines, limiting ischemic injury in the myocardium and initiating
efficient reparative mechanisms. We highlight recent developments in the controversial
auricular vagal neuro-circuitry and how they may relate to activation of the cholinergic
anti-inflammatory pathway.
Conclusion: Emerging published data suggest that auricular VNS is an inexpensive
healthcare modality, mediating the dynamic balance between pro- and anti-inflammatory
responses in cardiac macrophages and ameliorating cardiac ischemia/reperfusion injury.
Keywords: auricular vagal nerve stimulation, macrophage polarization, myocardial infarction, cholinergic anti-
inflammatory pathway, ischemia/reperfusion injury
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INTRODUCTION
Ischemic heart diseases, particularly myocardial infarction (MI),
remain a primary factor for mortality and morbidity worldwide.
A recent observational study of a European cohort revealed
similar mortality rates (∼49%) for both acute and chronic MI,
highlighting the poor prognosis (Kadesjö et al., 2019). The
American Heart Association reported that one third of total
deaths for individuals over 35 years of age in the United States
were associated with cardiovascular disorder (CVD) (Benjamin
et al., 2018). The disease progression is alarming, as 43.5% of adult
Americans are projected to have CVD in 2035 with public health
expenditure potentially reaching up to USD 1.1 trillion.
Initial therapy for MI aims to promptly reperfuse the infarct
myocardium. This can be achieved pharmacologically through
thrombolytic therapy to break up clots within the artery or
percutaneous coronary intervention to widen the narrowed
artery (Rentrop and Feit, 2015). However, ischemia/reperfusion
(I/R) injury is paradoxical to the restoration of the blood
flow and is associated with poor prognosis in MI patients
(Huang and Frangogiannis, 2018). This is partially due to
augmented inflammation during post-reperfusion therapy and
exaggeration of apoptosis (Yao et al., 2019). To date, few anti-
inflammatory agents are used in post-MI management despite
strong association of inflammatory cytokine imbalance with MI
pathogenesis (Huang and Frangogiannis, 2018). Early attempts
showed a lower risk of ischemic cardiovascular events in MI
patients with daily administration of colchicine, a potent anti-
inflammatory medication (Tardif et al., 2019). The cardiac
benefits of anti-inflammatory agents remain controversial since
non-steroidal anti-inflammatory drugs (NSAIDs) increase the
likelihood of first admission for cardiovascular events in patients
with no history of heart disease (Huang et al., 2019). There
is also a tendency toward fatal infection in MI patients with
multiple comorbidities following monoclonal antibody treatment
targeting interleukin-1β, highlighting the need for careful clinical
considerations (Ridker et al., 2018).
There is growing interest in the utilization of vagal nerve
stimulation (VNS) as a non-pharmacological approach in
mitigating inflammation in myocardial I/R injury (Wang
et al., 2014; Uitterdijk et al., 2015; Yu et al., 2017). The
interplay between the peripheral anti-inflammatory response
and central nervous activation is thought to be mediated via
a cholinergic anti-inflammatory pathway (CAP). This concept
was first reviewed by Tracey (Tracey, 2002), indicating that
excessive cytokine production in response to microbial invasion
or injury is attenuated by VNS. At the cellular level, the
neurotransmitter acetylcholine (ACh) is released following vagal
activation, modulating both electrical and mechanical functions
of the heart. ACh binds to the α7 nicotinic acetylcholine
receptor (α7nAChR), an ionotropic receptor that presents in
the endothelial layer of heart tissues to modulate tonic activity
of the heart (Mazloom et al., 2013). α7nAChR also presents
widely in immune cells, specifically in the myocardium. In
MI-induced rats, activation of α7nAChR was linked with
immunomodulation, cardioprotection, reversal in MI prognosis,
including sympathetic hyperactivity as measured by heart
rate variability (HRV), and improved cardiac hemodynamic
function (Bezerra et al., 2017). Indeed, the autonomic balance
between sympathetic and parasympathetic branches is pivotal
in regulating the normal physiological functions of the
cardiovascular system—elevated sympathetic and decreased
parasympathetic activity is a common hallmark following MI
(Yokoyama et al., 2017). Significant experimental evidence
indicates that VNS provides cardioprotection against myocardial
I/R injury (Wang et al., 2014; Uitterdijk et al., 2015). The
cardioprotective properties attributed to direct VNS in MI
animals include improvement of ventricular function such
as a reduction of ventricular tachycardia and ventricular
arrhythmia, reduction of infarct size, attenuation of adverse
cardiac remodeling, improvement of left ventricular ejection
fraction (LVEF), and attenuation of myocardial interstitial
fibrosis (Uemura et al., 2010; Uitterdijk et al., 2015; Zhang
et al., 2016). In humans, delivering transcutaneous VNS (tVNS)
at the tragus provided equivalent cardioprotection in patients
with ST elevated myocardial infarction (STEMI) treated with
primary percutaneous coronary treatment (Yu et al., 2017).
This therefore aids with generating an initial evidence base
of the cardioprotective effects non-invasive vagal stimulation
can confer in MI patients (Wang et al., 2014; Stavrakis et al.,
2017; Zhou et al., 2019). While numerous studies reveal
the therapeutic benefits of invasive and non-invasive VNS
in I/R injured myocardium, the underlying cardioprotective
mechanism remains to be elucidated. In this review, we will focus
on the anti-inflammatory effects of VNS/tVNS specifically in the
macrophage subpopulations and how VNS/tVNS may provide
therapeutic benefit in cardiac I/R injury.
INFLAMMATORY CELL INFILTRATION AS
HALLMARKS FOR CARDIAC
ISCHEMIA/REPERFUSION INJURY
After restoring perfusion, a sterile inflammatory response is
activated to clear necrotic cellular debris. This inflammatory
response is characterized by endothelial barrier dysfunction
and the recruitment of inflammatory cells immediately after
reperfusion. The whole process is initiated by the release of
inflammatory signals from an extracellular matrix known as
danger-associated molecular patterns (DAMPs). The release of
protein DAMPs interacts with toll-like receptors on vascular
cells to trigger transcription of pro-inflammatory factors
via nuclear factor (NF)κB activation. This subsequently
perpetuates complementary inflammatory cascades, like
cytokines, chemokines, and adhesion molecules (Timmers
et al., 2012). While the primary role of chemokines is to
induce chemotaxis, together with adhesion molecules these
pro-inflammatory factors mediate infiltration of neutrophils
and monocytes into the injured myocardium. The presence
of adhesion proteins on the injured endothelial surface of the
myocardium leads to sequestration of free-flowing leukocytes
followed by a slow-roll along the vessels in the course of blood
circulation. The infiltrated neutrophils yield potent cytotoxic
effects by releasing proteolytic enzymes, such as chymotrypsin
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and trypsin, to induce apoptosis in inflamed cells (Trevani et al.,
1996). Monocytes also infiltrate into the injured myocardium
along with neutrophils. The firm adhesion of monocytes to
the endothelium is facilitated by chemokines, such as C-C
motif chemokine ligand 2 (CCL2) and interleukin (IL)-8, which
eventually leads to extravasation across the endothelium (Dewald
et al., 2005). Recruitment of monocytes into the infarcted
region can give rise to monocyte-derived macrophages with
pro-inflammatory properties (Honold and Nahrendorf, 2018).
Secondary to the phagocytic role, the presence of macrophages
in the infarcted myocardium is linked to an anti-inflammatory
reparative phase. The transition from pro- to anti-inflammatory
states is orchestrated between cardiac (e.g., cardiomyocytes,
endothelial cells, fibroblasts) and inflammatory cells (e.g.,
neutrophils, monocytes, macrophages) (Honold and Nahrendorf,
2018). This multilayered signaling contributes to wound healing
and scar formation to prevent cardiac rupture. The process
is highly regulated; disturbance in the balance between the
two inflammatory states may exacerbate injury and contribute
to further heart dysfunction (Ong et al., 2018). As such, an
overextended active inflammatory phase can lead to sustained
tissue damage, improper tissue healing, such as defective scar
formation, enlargement of the infarct tissue area, adverse cardiac
remodeling, chamber dilatation, and ultimately decompensation
in cardiac pumping ability. Currently, there are limited
immunomodulatory or anti-inflammatory therapeutic regimes
being implemented in clinical settings to treat acute MI. Targeting
inflammatory cascades post-MI and initiating treatment regimes
during the early phases of I/R injury have been recommended
(Ong et al., 2018). However, if anti-inflammatory regimes are
given too early, premature attenuation of the proliferative phase
can occur, causing cardiac rupture or aneurysm formation.
PREVENTION OF CARDIOVASCULAR
EVENTS VIA ANTI-INFLAMMATION
Although the primary function of the innate immune reaction
is to promote homeostasis of tissue repair during post-
reperfusion therapy, this may however act as a double-
edged mechanism, resulting in further disease progression.
In this respect, a dysregulated innate immune response has
preconditioned a plethora of unnecessary pro-inflammatory
releases. Acknowledgment of the double-edged mechanism of
the inflammation in MI is clinically important as heart failure
(HF) patients with reperfusion surgery have poor prognoses.
This therefore presents medical practitioners with significant
therapeutic challenges (Kadesjö et al., 2019). Results from clinical
trials targeting inflammatory factors in MI are inconsistent
and not always in line with initial hypotheses. An earlier
prospective cohort study among individuals above 55 years
old (n = 164,862) showed that NSAIDs increased the risk
of a relapse in subjects with existing cardiovascular diseases,
calling for careful drug prescription (Feenstra et al., 2002).
Indeed, broad anti-inflammatory therapy may inhibit important
repair pathways and negatively impact patients with MI (Huang
and Frangogiannis, 2018). Conversely, inhibition of specific
inflammatory modulators may present promise. For instance,
canakinumab is an anti-IL1β biologic used to treat autoimmune
diseases such as rheumatoid arthritis. In a randomized, double-
blind trial, the Canakinumab Anti-inflammatory Thrombosis
Outcome Study (CANTOS) tested the effects of three doses of
canakinumab (50, 150, 300 mg) delivered subcutaneously every
3 months in 10,061 patients with a history of MI. Analysis of
the primary study endpoints revealed that 150 mg reduced the
relative risk of cardiovascular events and hospitalization by 15%
compared to placebo (Ridker et al., 2017). In a dose-dependent
manner and without affecting cholesterol levels, canakinumab
treatment also reduced systemic inflammation biomarkers, such
as high-sensitivity C-reactive protein (hsCRP) and IL-6, which
have been associated with the presence of heart disease (Ridker
et al., 2017; Ridker et al., 2018). However, the use of canakinumab
was associated with a higher incidence of fatal infection (Ridker
et al., 2017). In another study, The Cardiovascular Inflammation
Reduction Trial (CIRT) examined the cardiovascular benefits of
low-dose methotrexate, a broad-spectrum immunosuppressant
drug, in MI patients (n = 5,500) (Ridker et al., 2019). Although
CIRT had similar primary study endpoints to CANTOS, the use
of methotrexate failed to reduce the risks of cardiovascular events
and circulating inflammatory levels. Non-basal-cell skin cancers
were also associated with methotrexate treatment in MI patients,
hence calling for early termination of the study. While the
CANTOS trial supported the therapeutic plausibility of targeting
specific inflammatory pathways in MI, clinical implementation
of anti-inflammatory agents in high-risk cardiovascular disease
patients still requires further investigation until the risk–benefit
trade-off has been clarified.
HETEROGENEITY OF CARDIAC
MACROPHAGES IN MYOCARDIAL
INFARCTION
Macrophages are key regulators for cardiac inflammatory
reactions in post I/R cardiac remodeling. Pro-inflammatory
macrophages in the ischemic myocardium may originate from
resident monocytes which are capable of switching their
biological functions based on microenvironmental cues (Zhao
et al., 2019). Indeed, an integrative computational model suggests
activation of pro-inflammatory macrophages can be induced
in the presence of specific cytokines such as tumor necrosis
factor (TNF)α, interferon (IFN)γ, or hypoxic factors which
are released by injured cellular components as innate immune
responses (Zhao et al., 2019). The secretion of pro-inflammatory
cytokines activates cardiac fibroblasts which in turn produce
matrix proteases [matrix metalloproteinase (MMP)2, MMP9]
in addition to other pro-inflammatory cytokines such as IL-
1β and IL-6 (Ploeger et al., 2013). Proteases are pivotal in
degrading the extracellular matrix to initiate tissue remodeling.
The innate immune response of fibroblasts therefore provides
a positive feedback loop, amplifying the pro-inflammatory
microenvironment, to facilitate the clearance of necrotic cells
within the ischemic and peri-ischemic regions (O’Rourke et al.,
2019). During 5–7 days post-reperfusion, resident macrophages
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in the ischemic murine heart display a pro-reparative genetic
signature (Mouton et al., 2018). These macrophages release anti-
inflammatory cytokines, such as IL-10, which limit activation
and proliferation of pro-inflammatory subtypes through the
signal transducer and activator of transcription (STAT)3 pathway
(Ploeger et al., 2013). Anti-inflammatory macrophages secrete
numerous growth factors, such as vascular endothelial growth
factor (VEGF) and transforming growth factor (TGF)β, that
increase the capacity of matrix components to produce and
deposit collagen for scar formation. PET/MRI in MI mice that
received RNA interference treatment to target pro-inflammatory
macrophages showed improvements in infarct inflammation and
preserved LV function (Majmudar et al., 2013). Subsequent
genomic and proteomic analyses revealed attenuation of the pro-
inflammatory macrophage population in the infarcted region
and elevated secretion of anti-inflammatory cytokines such as
IL-10 and IL-6 (Majmudar et al., 2013). This suggests that
prolonged inflammatory macrophage activity may exacerbate
tissue remodeling post-infarction.
MACROPHAGE POLARIZATION AS A
THERAPEUTIC TARGET IN
MYOCARDIAL INFARCTION
The hyperactivity in pro-inflammatory macrophages can be
regulated by the activation of α7nAChR which is highly expressed
on the surface of inflammatory cells (Zhang et al., 2017).
Examination in a murine model with lipopolysaccharide (LPS)-
induced acute lung injury showed attenuation of inflammatory
responses in the presence of an α7nAChR agonist (Wang
et al., 2019). The anti-inflammatory action of α7nAChR was
associated with protection against lung injury and polarization
of macrophages with anti-inflammatory subtypes (Wang et al.,
2019). The restorative benefit of the cholinergic modulation
is also reported in MI animals where inhibition of ACh
degradation with pyridostigmine showed dense macrophages
with anti-inflammatory phenotypes in ischemic and peri-
ischemic regions (Rocha et al., 2016; Bezerra et al., 2017).
Interestingly, despite equivalent numbers of total macrophages
counted in both vagal and non-vagal activated groups, more
immunoreactive pro-inflammatory subtypes were observed in
the non-stimulated animals (Rocha et al., 2016). This suggests an
enhancement of macrophage plasticity, with anti-inflammatory
predominance in the presence of cholinergic agents. Indeed,
microglia cocultured with LPS endotoxins resulted in aggravated
pro-inflammatory release of cytokines, such as IL-1 and IL-
6, within the first few hours (Zhang et al., 2017). However,
ACh treatment both pre- and post-LPS stimulation suppressed
the pro-inflammatory cytokine release and increased production
of anti-inflammatory cytokines, such as IL-4 and IL-10. The
pro-inflammatory suppressive effect of ACh was inhibited in
α7nAChR knockdown rats without affecting anti-inflammatory
cytokine levels. It therefore seems that shifting macrophages
toward anti-inflammatory subtypes by vagal activation alters
the cellular milieu, by modulating pro-inflammatory release and
maintaining the anti-/pro-inflammatory protein balance.
The anti-inflammatory mechanism of VNS remains
unclear. One hypothesis is that vagal activation inhibits
NFκB translocation and phosphorylation, therefore curtailing
inflammatory signaling (Han et al., 2014). During acute MI,
inflammatory signals (e.g., TNFα, IL-6) are released by the
injured cells and bind to toll-like receptors to assist with the
translocation and phosphorylation of NFκB, a transcriptional
activator for inflammatory response (Han et al., 2014). It has
also been postulated that α7nAChR activation triggers the
CAP via Janus kinase (JAK)2-STAT3 signaling, a known negative
regulator for inflammatory responses (De Jonge and Ulloa, 2007).
Interestingly, in vivo studies reported elevated pro-inflammatory
macrophages with activated STAT3 in hypertension, a known
predisposing factor for MI (Loperena et al., 2018). Further, an
in vitro study using endothelial cells revealed an activation of
STAT3 due to an increased endothelial stretch (Loperena et al.,
2018). Meanwhile, inhibition of STAT3 prevented the monocyte
inflammatory response toward a dysfunctional endothelium
(Loperena et al., 2018). Hence, it is pivotal to understand the
mechanistic interventions of α7nAChR activation to enhance
STAT3 activity in mediating anti-inflammatory roles in MI and
other related conditions.
CURRENT DEVELOPMENT IN VAGAL
NEUROMODULATION TECHNIQUE AS A
THERAPY FOR MYOCARDIAL
INFARCTION?
Modulation of vagal nerve activity has emerged as a potential
non-pharmacological therapy for HF after MI. It is generally
accepted that HF is associated with autonomic nervous system
(ANS) imbalance, characterized by enhanced sympathetic tone
and withdrawal of parasympathetic activity. Evidence in healthy
humans shows that tVNS reduces muscle sympathetic nerve
activity, thus suggesting the plausibility of the nerve modulation
technique to restore imbalance in the ANS (Clancy et al.,
2014). VNS/tVNS also appears to attenuate the progressive loss
of ventricular function from post-ischemic cardiac remodeling
(see Table 1 for a summary). For instance, chronic vagal
stimulation (for 6 weeks) in post-MI rats showed improvement
in LV end diastolic pressure and lower normalized biventricular
weight compared to the untreated rats (Li et al., 2004).
Similar observations were obtained from a combination therapy
with metoprolol and chronic VNS in MI rats; improvements
in LV function were associated with better prognosis in
comparison to metoprolol alone (Li H. et al., 2019). Although,
both studies reported no statistically significant changes in
infarct size following VNS (Li et al., 2004; Li M. et al.,
2019). Infarct size reduction has been consistently reported
in other VNS-MI studies involving activation of α7nAChR
(Chen et al., 2016; Kiss et al., 2017; Buchholz et al., 2018;
Nuntaphum et al., 2018). The discrepancies could be attributed
to different stimulation protocols and parameters (Uitterdijk
et al., 2015; Chen et al., 2016; Buchholz et al., 2018;
Nuntaphum et al., 2018).
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TABLE 1 | Studies on invasive vagal neuromodulation in animal models of myocardial infarction.
Invasive VNS
Author Species N MI model Stimulation protocol Stimulation parameters Myocardial infarction
outcomes
Nuntaphum et al., 2018 Swine 30 I/R VNS applied on the left
cervical vagal trunk at the
onset of ischemia (60 min),
continued until the end of
reperfusion.
3.5 mA, 0.5 ms, 20 Hz Reduction in infarct size,
arrhythmia score, oxidative
stress, apoptosis. Intact
contralateral vagal efferent
required to provide better
cardioprotection.
Chen et al., 2016 Dog 30 I/R VNS applied on the left
cervical vagal trunk for
120 min during reperfusion.
20 Hz, 0.1 ms, 80% below
voltage threshold.
Reduction in infarct size,
myocardial neutrophil
infiltration, inhibition of oxidative
stress and apoptosis.
Uitterdijk et al., 2015 Swine 23 I/R VNS applied on left vagal
nerve 5 min prior to
reperfusion and continued
until 15 min of reperfusion.
10 mA, 0.3 ms, 25 Hz Reduction in infarct size, area of
no-reflow, neutrophil and
macrophages infiltration in the
infarct area. NO-synthase
activity was required for VNS
cardioprotection.
Li M. et al., 2019 Rat 100 CHF VNS applied on right
cervical vagus nerve with a
duty cycle of 16.7% (10 s
on/50 s off) for 24 h and
last for 6 weeks.
0.2 ms, 20 Hz VNS + metoprolol treatment
(VSM) improved 50-day survival
rate, cardiac index and
maximum left ventricular
pressure (LV + dp/dtmax). VSM
also reduced heart rate,
normalized biventricular weight,
left ventricular end diastolic
pressure (LVEDP), right arterial
pressure, plasma
norepinephrine, epinephrine
and brain natriuretic peptide
(BNP). VNS exerts its
cardioprotection independent
of anti-beta-adrenergic
pathway.
Li et al., 2004 Rat 85 CHF VNS applied on right
cervical vagus nerve for
10 s every minute for
6 weeks.
0.2 ms, 20 Hz,
0.1–0.13 mA (adjusted for
each rat)
VNS improved 140-days
survival rate, LV + dp/dtmax
and also reduced LVEDP,
normalized biventricular weight,
plasma norepinephrine and
BNP.
Buchholz et al., 2018 Rat 59 I/R Right cervical vagus nerve
was stimulated for 10 min
prior to ischemia or the
initial 10 min during
reperfusion
0.1 ms, 10 Hz Both preischemic VNS and
reperfusion VNS reduced heart
rate and infarct size.
Preischemic VNS provides
cardioprotection via
Akt/GSK-3β muscarinic
pathway while reperfusion VS
via α7nAchR activation.
Kiss et al., 2017 Rat 76 I/R Right cervical nerve was
stimulated for 2 h during
reperfusion.
0.5 ms, 15 Hz, 0.1–1 mA VNS reduced infarct size and
reversed the upregulation of
arginase activity induced by IR.
These effects were abolished
by α7nAChR blockade.
Perhaps unsurprisingly, clinical trials of VNS also report
contradictory therapeutic endpoints (see Table 2 for a summary).
A 6-month pilot study of VNS (CardioFitTM) in patients with
ventricular dysfunction (n = 8) found significant reductions in
cardiac end systolic volume as well as improvement in New York
Heart Association (NYHA) class function (Schwartz et al., 2008).
De Ferrari et al. (2011) extended this study into a multicenter,
two-stage trial (n = 32) where similar data collection points were
combined with an optional 1-year follow-up. VNS successfully
improved patient NYHA class, quality of life, exercise ability, LV
systolic volume, as well as LVEF (De Ferrari et al., 2011). The
Autonomic Neural regulation THerapy to Enhance Myocardial
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TABLE 2 | Clinical trials on invasive vagal neuromodulation in patients with heart failure.
Clinical trials
Author Acronym N Sampling group Stimulation protocol Stimulation parameters Cardioprotective
outcomes
Schwartz et al.,
2008
8 (i) 18–75 years old (ii) Left
ventricular ejection
fraction < 35% (iii) History
of CHF in NYHA class II–III
(iv) Screening Holter ECG
average 24 h heart rate
≥65 beats/min (v)
Occurrence of ≥2 episodes
of heart rate ≥80 without
physical exercise and
capable of 6 min walk test.
Stimulation started
2–3 weeks after Cardiofit
implantation. 3–4 visits/week
were performed during the
3 weeks titration phase to
slowly increase the current
until discomfort was
reported. Current was set
below the point where
discomfort was reported.
Follow up sessions were
carried out 1,3 and
6 months after optimization
to evaluate patients.
Delivery of 1 ms pulse/beat
70 ms after R wave with an
amplitude of 2 mAmp.
Intermittent pulse
application with 2–10 s ON
time followed by 6–30 s
OFF time.
VNS was reported to be
safe and tolerable on
patients with mild side
effects. VNS also
significantly improved
patient’s NYHA class,
Minnesota quality of life
score and left ventricular
end systolic volume
(LVESV).
Premchand
et al., 2016
ANTHEM-HF 60 NYHA class II-III heart
failure patients with ≤40%
of left ventricular ejection
fraction (LVEF).
Patients were implanted with
VNS device (Demipulse
Model 103 pulse generator
and PerenniaFLEX Model
304 lead, Cyberonics,
Houston, TX, United States)
with 1:1 randomized lead
placement to either left or
right cervical vagus nerve.
During the 10 weeks titration
phase, stimulation
parameters were
systematically adjusted.
During the 6 months follow
up period, 49 patients (23
left sided, 26 right sided)
consented to take part in
extended follow up visits at 9
and 12 months.
250 µs, 10 Hz,
2.0 ± 0.6 mA
VNS was safe and
well-tolerated in patients
with minimal side effects.
VNS significantly
improved patient’s LVEF
and LVESD at 6 and
12 months with the
exception of LVESV
improving at 12 months.
VNS also improved
NYHA class, 6 min walk
distance and scores on
the Minnesota Living with
Heart Failure
Questionnaire.
De Ferrari et al.,
2017
NECTAR-HF 96 NYHA class II or III patients
with LVEF ≤35% and LV
end diastolic dimension
(LVEDD) ≥55 mm.
In the first phase, patients
were implanted with Boston
Scientific VNS system and
randomized with 2:1 ratio
into group receiving
standard medical treatment
with active VNS vs. group
receiving standard medical
treatment with inactive VNS
for 6 months. Inactive VNS
was activated after
6 months. In the second
phase, patients were
evaluated once again after
18 months.
20 Hz, 300 µs0, 10 s ON
time followed by 50 s OFF
time, ≤4 mA.
VNS failed to show
significant improvement
on cardiac function in
terms on LVESV, LVESD,
and LVEF. However, VNS
was able to improve
NYHA class for all
patients. Observation of
heart rate effect using
heat map technique
revealed that patients in
NECTAR-HF had
significantly less
recruitment of fibers
involved in heart rate
changes.
Gold et al.,
2016
INOVATE-HF 707 NYHA class III patients with
LVEF ≤%, LVEDD of
50–80 mm and QRS
duration <120 ms.
Patients were implanted with
CardioFit system and
underwent 3:2 ratio of
randomization into group
receiving standard medical
treatment + VNS vs.
standard medical treatment
only. Follow-up evaluations
were carried out at 3 month
intervals during the 18
months post-implant,
followed by 6 month
intervals for overall status.
3.9 ± 1.0 mA VNS did not reduced
mortality of patients and
did not induce reverse
remodeling. Nonetheless,
VNS significantly
improved NYHA class,
6 min walk duration and
quality of life measures.
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function in Heart Failure (ANTHEM-HF) study assessed the
effects of therapy on LV structure and function in patients with
chronic stable HF. Stimulating either the left or the right side
of the vagus nerve in HF patients significantly improved cardiac
contractility as measured from LVEF and pro-brain natriuretic
peptide (BNP) (a plasma HF marker) (Premchand et al., 2016).
However, a randomized sham control trial [Neural Cardiac
Therapy for Heart Failure (NECTAR-HF)] failed to demonstrate
any significant changes in the endpoint measures after 6 months
of right vagal stimulation (Zannad et al., 2015). Additionally,
a multinational randomized trial [Increase of Vagal Tone in
Heart Failure (INOVATE-HF)] showed the risk of death or
events among HF patients was not improved in the VNS-treated
group (Gold et al., 2016). Despite conflicting cardiac functions as
primary endpoints, VNS studies agreed that long-term therapy
improved overall quality life. Inconclusive outcomes from these
VNS clinical trials are potentially due to heterogeneity in study
samples where different patient groups have specific clinical
presentations and therapeutic needs. Differences in outcomes
may also be compounded by the VNS protocols that seem to vary
from study to study (Li M. et al., 2019).
Activation of the vagus nerve may be achieved non-invasively
through electrical stimulation of select auricular dermatomes
with vagal afferent innervation (Peuker and Filler, 2002). Indeed,
the vagus nerve has an auricular branch, thought to innervate the
tragus, concha, and cymba concha, to which electrical stimulation
can be applied. This involves using a transcutaneous electrical
nerve stimulator (TENS) machine connected to auricular clips
to deliver small, pain-free, just perceptible electrical impulses to
the auricular dermatome of interest (usually the tragus, concha,
or cymba concha). As such, tVNS could be useful for many MI
patients especially as it is painless, inexpensive (the cost of a
TENS machine), simple to administer (i.e., can be performed
in the comfort of one’s own home), well-tolerated, and highly
convenient, particularly for patients who have restrictions on
pharmacological therapies (Wang et al., 2015).
Applying low-level tragus stimulation (20 Hz, 1 ms, duty cycle
of 5 s on 5 s off) in dogs with healed MI for 90 days attenuated
ventricular remodeling, as recognized by a smaller infarct size
and better cardiac contractile and diastolic functions (Wang
et al., 2014). Normally, in post-MI (without any stimulation
or sham control), cardiac tissue starts to develop scars and
the level of fibrosis is influenced by enhanced sympathetic
nerve activity (Wang et al., 2014). However, the group that
received low-level tragus stimulation exhibited reductions in
plasma norepinephrine (NE) levels, suggesting that central
sympathoinhibition may be responsible for the amelioration of
the post-MI remodeling (Wang et al., 2014). In a study by Zhou
et al. (2019) on Dahl salt-sensitive rats, inflammatory responses
within the LV were successfully abrogated following 4 weeks of
tVNS (20 Hz, 0.2 ms, 2 mA). In this model, cardiac injury on the
LV signifies maladaptive physiological reactions due to prolonged
elevations in blood pressure (Zhou et al., 2019). However, non-
invasive VNS prevented hypertension and deteriorations in LV
diastolic pumping function (Zhou et al., 2019).
Despite promising animal studies, evidence to support the
cardioprotective effects of auricular VNS in real MI patients
is still lacking. However, initial evidence comes from a
trial in MI patients with impaired LV contractility during
preoperative management where tVNS was delivered for 15 min
and repeated for 10 consecutive days (Zamotrinsky et al.,
2001). The study reported an increased density of cardiac
noradrenergic plexuses, improved hemodynamic properties, and
reduced incidence of transient heart failure during the post-
operative period. Another study was performed in patients who
underwent balloon angioplasty within 12 h of MI symptom
onset (Yu et al., 2017). Low-level tVNS treatment (20 Hz,
1 mA) applied on the right tragus for 2 h immediately
after the procedure successfully attenuated MI reperfusion
injury. The cardioprotective characterizations were recorded
after 7 days where blood inflammatory markers, incidence of
ventricular arrhythmia, and echocardiography cardiac functions
were improved. In another study, similar tVNS parameters
(20 Hz, 1 mA) were tested in patients with diastolic dysfunction
(n = 10) (Stavrakis et al., 2017). One hour of tVNS therapy
successfully improved diastolic function (increased by 2.7%)
and was associated with a shift in HRV index toward vagal
predominance (Stavrakis et al., 2017). These early works (see
Table 3 for a summary) therefore suggest that tVNS could
provide cardioprotective effects for patients with MI, reinforcing
the need for considerably more research in this area.
PERSPECTIVES AND FUTURE STUDIES
How Does Auricular Stimulation Activate
the Vagus Nerve?
It is important to note that although other nerves innervate the
auricle, e.g., the great auricular nerve and the auriculotemporal
nerve, they are often underappreciated and findings are based on
one research study (Peuker and Filler, 2002; Burger and Verkuil,
2018). Our previous neuro tracing study in rats showed dense
termination of nerve afferents from the tragus into the ipsilateral
dorsal region of the upper cervical spinal cord between C2 and
C4 (Mahadi et al., 2019). Further neurophysiology recordings
from the central sympathetic trunk showed acute reductions
in sympathetic activity after tragus stimulation; equivalent as
per reported in healthy humans (Clancy et al., 2014; Mahadi
et al., 2019). Interestingly, the inhibitory effect persisted despite
cervical vagal sectioning ipsilateral to the stimulation point.
These inhibitory effects then became attenuated following an
incision on the upper cervical afferent nerve roots. As a result,
this prompts for careful interpretation of VNS, particularly with
the transcutaneous method.
Intriguingly, neuroimaging studies repeatedly reported
involvement of vagal associated regions in the brain stem which
are ipsilateral to the stimulation site in the ear, such as the nucleus
tractus solitarius (NTS), spinal trigeminal nucleus, and locus
coeruleus (Yakunina et al., 2017). This unlocks an avenue for
discussion regarding whether auricular vagal neurostimulation is
subserved by the deep and superficial dorsal horn neural activity:
perceived from “heat/electrical” signal sensations triggered
from the skin. Dorsal horn neurons are typically associated
with conveying sensory information from the skin and internal
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TABLE 3 | Studies of cardioprotection by transcutaneous VNS.
Transcutaneous VNS
Author Species N MI model Stimulation protocol Stimulation parameters Myocardial infarction/cardioprotective outcomes
Wang et al.,
2014
Dog 30 Healed MI Low level tragus stimulation
(LLTS) was applied at the
bilateral tragus of the external
auditory canal in conscious
dogs for 4 h (7–9 am, 4–6 pm).
20 Hz, 1 ms, 5 s on and 5 s off
duty cycle
Treatment of LLTS significantly attenuated left atrial (LA) and left
ventricular (LV) dilatation, improved LV contractile and diastolic
function and also significantly reduced infarct size and cardiac
fibrosis. Protein expressions of transforming growth factor β1
(TGF-β1), matrix metallopeptidase 9 (MMP-9), collagen I and
collagen III were significantly attenuated through treatment of
LLTS. Plasma high specific C-reactive protein (hs-CRP),
norepinephrine (NE) and N-terminal pro B-type natriuretic
peptide (NT-proBNP) were also significantly reduced in LLTS
group.
Zhou et al.,
2019
Rat 48 Heart failure
with preserved
ejection fraction
(HFpEF).
LLTS was applied at the
auricular concha region in
anesthesized rats 30 min daily
for 4 weeks.
20 Hz, 0.2 ms, 2 mA Treatment of LLTS significantly attenuated the elevation of blood
pressure, reduced LV hypertrophy, inhibited the deterioration of
LV diastolic function and attenuated LV inflammatory cell
infiltration and fibrosis compared with sham control. Likewise,
improvement of LV circumferential strain was also observed
through treatment with LLTS. Expression of pro-inflammatory
and pro-fibrotic genes were downregulated in LLTS group
suggesting that LLTS preserved LV function possibly through
the suppression of myocardial pro-inflammatory and pro-fibrotic
gene expression.
Zamotrinsky
et al., 2001
Human 18 Coronary artery
disease (CAD)
with stable
angina pectoris
Auricular vagus nerve was
stimulated using acupuncture
needle for 10 stimulation
procedures that lasted for
15 min and repeated for
10 days.
3 Hz, 1.5 ms, 0.2–1.5 mA VNS treatment conveyed an anti-anginal effect and reduced
blood pressure and heart rate. Improvement of LVEF and left
ventricular diastolic filling were also observed in VNS group.
Electrocardiograms of VNS group reported a shortening of QRS
and QT duration, no changes on PQ interval and an
improvement of T-wave. VNS treatment also attenuated the
progression of heart failure in patients.
Yu et al., 2017 Human 95 ST-elevation
myocardial
infarction
(STEMI)
STEMI patients that underwent
percutaneous coronary
intervention (PCI) were given
LLTS at right tragus for 2 h after
balloon dilatation.
20 Hz, 1 ms, 50% below
threshold, duty cycle 5 s on
and 5 s off
Treatment of LLTS significantly attenuated the occurrence of
reperfusion associated ventricular arrhythmia during first 24 h.
The area under curve for level of creatine kinase-MB and
myoglobin were significantly reduced by LLTS 72 h after
reperfusion. In addition, level of NT-proBNP was significantly
reduced by LLTS at 24 h and 7 days post-reperfusion.
Significant improvements of inflammation, LVEF and wall motion
index were observed as well in LLTS group.
Tran et al.,
2019
Human 24 Diastolic
dysfunction and
preserved LVEF
LLTS was applied on patients
for two sessions. Each session
lasted for 1 h and was
separated by at least 1 day to
1 week.
20 Hz, 200 µs, 1 mA LLTS treatment improved left ventricular global longitudinal
strain and induced favorable alteration of heart rate variability
(HRV) frequency domain parameters in terms of high frequency
(HF), low frequency (LF) and LF/HF ratio.
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organs to the spinothalamic tract for pain signaling (Todd,
2010). Of note, auricular nerve stimulation was demonstrated
to modulate sympathetic tone potentially through dorsal horn
neural connectivity (Clancy et al., 2014; Mahadi et al., 2019).
Despite not being widely recognized, the functionality of neurons
in the cervical dorsal horn can also be observed in autonomic
control of the cardiovascular system (Todd, 2010). In fact, spinal
cord stimulation (SCS) at the lumbar region has been linked
with increased vagal tone measured from HRV in patients
with severe pain (Goudman et al., 2019). In addition, lumbar
SCS demonstrated α7nAChR-mediated microglia inhibition
in rabbits with spinal cord ischemia injury (Li H. et al., 2019).
Anterograde tracing in rats demonstrates that the neurons of
the superficial laminae of the dorsal horn terminate in the NTS
which is an autonomic-vagal relay center (Potts et al., 2002).
Hence, it is worth considering that the therapeutic benefits
elicited by auricular neurostimulation may also be mediated by
spinal activation (Figure 1).
Proposed Neural Mechanisms for the
Cholinergic Anti-Inflammatory Pathway
The exact interaction between the transcutaneous vagus
nerve and neuro-immune axis remains to be elucidated, and
FIGURE 1 | Schematic of potential pathways for how auricular stimulation
could provide cardioprotection against cardiac remodeling in myocardial
infarction (MI). Electrical stimuli applied on the auricle directly activate the
nucleus tractus solitarius (NTS) through the auricular branch of the vagus
nerve (ABVN) afferents. The NTS is also potentially activated in secondary
order from somatosensory neurons in the upper cervical spinal cord. The NTS
is the central control for autonomic functions and activates the
hypothalamus–pituitary–adrenal axis to release anti-inflammatory cortisol.
Initiation of action potentials in the NTS also sends signals to cell bodies in the
dorsal motor nucleus of the vagus (DMV) and nucleus accumbens (NA) which
give rise to vago-vagal and vago-sympathetic reflexes.
several mechanisms have been proposed (Bonaz et al., 2017).
One theory proposes that vagal afferent signaling propagates
to the hypothalamus–pituitary–adrenal (HPA) axis. During
peripheral inflammation, a surge of IL-1β occurs in the
brain (Hosoi et al., 2000). Vagal afferents receive input from
glomus cells of paraganglia which have a binding affinity for
inflammatory cytokine IL-1β (Goehler et al., 1997). This activates
NTS noradrenergic A2 neurons and subsequently relays the
information to corticotrophin-releasing factor (CRF) neurons
located in the parvo-cellular region of the paraventricular nucleus
of the hypothalamus (PVH). CRF stimulates the pituitary gland
to secrete adrenocorticotropic hormone (ACTH) which in turn
induces adrenal production of glucocorticoids for the inhibition
of peripheral inflammation. Electrical stimulation of vagal
afferents in immune challenged rats upregulates CRF mRNA
expression in the hypothalamus, increasing the production of
plasma ACTH and corticosterone (Hosoi et al., 2000; De Herdt
et al., 2009). In healthy individuals, targeting vagal innervation
in the cymba conchae prevented a decline in salivary cortisol
levels, a glucocorticoid stress hormone, suggesting activation of
the HPA axis during tVNS (Warren et al., 2019).
Other proposed pathways involve the activation of vagal
efferents. Earlier work by Borovikova et al. (2000) demonstrated
that bilateral stimulation to the distal end of a vagotomized
nerve trunk suppressed systemic inflammatory responses in
endotoxemic rats. ACh released by the nerve endings inhibited
pro-inflammatory cytokine release by human macrophages
in vitro. The neuro-immune benefits elicited from vagal efferent
activation were silenced in α7-cholinergic receptor-deficient
mice during endotoxemia (Wang et al., 2003). Thenceforth,
FIGURE 2 | Activation of the cholinergic anti-inflammatory pathway inhibits
pro-inflammatory release by macrophage. (1) During ischemia,
hypoxia-activating factors are released by injured cells and cause activation of
the nuclear factor (NF)-κB signaling pathway to induce pro-inflammatory
cytokine release. Cardiac macrophages undergo phenotypic and metabolic
reprogramming within a week of myocardial infarction (MI)—from high
pro-inflammatory activity into a pro-reparative signature. (2) Acetylcholine
released from the vagus nerve terminates in α7 nicotinic acetylcholine
receptors (α7nAChR) expressed on macrophages, and these inhibit the
release of pro-inflammatory cytokines.
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the immune-vagal neural interaction was commonly referred
to as the CAP. However, synaptic connection from the vagus
nerve to the spleen, a lymphoid organ that is primarily
involved in the production of immune cells, has been proven
sparse (Bratton et al., 2012). Surgical ablation of the splenic
nerve in rats with endotoxemia abrogated the downregulation
of pro-inflammatory cytokines with VNS, highlighting its
functional role in mediating the CAP (Rosas-Ballina et al.,
2008). Similar observations were obtained in catecholamine-
depleted rats, denoting the synergistic effects of sympathetic
nervous activity in the CAP. Electrical stimulation of the splenic
nerve controls systemic inflammation, prevents septic shock,
and restores neuromodulation benefit in α7nAChR-knockout
mice (Vida et al., 2011a). However, pharmacological inhibition
of β2-adrenoreceptors in endotoxemia rats prevented the anti-
inflammatory potential of splenic nerve stimulation (Vida et al.,
2011b). As such, the splenic nerve may act as an intermediary
link between both autonomic nervous activities and the CAP
response (Figure 1). Although controversial, some studies
suggest sole sympathetic-splenic nerve input into the “cholinergic
anti-inflammatory reflex” without the influence of vagus nerve
activation (Martelli et al., 2014, 2019). While this has been shown
in an endotoxemia sepsis model, this does not fully account
for the effects of vagal neuromodulation observed from other
experimental models, e.g., heart failure (Kiss et al., 2017).
Investigating the Effects of
Transcutaneous Vagus Nerve Stimulation
in Individuals With Myocardial Infarction
Collectively, there is considerable preclinical evidence suggesting
that VNS/tVNS is associated with beneficial cardioprotective
effects (Wang et al., 2014; Zhou et al., 2019). However, the
translational benefit of VNS in human trials has proven difficult
(Statz and Olshansky, 2019). Hence, finding a good foundation
for VNS/tVNS research which further examines the potential
impact of this novel therapy on the lives and health of individuals
with cardiovascular conditions is warranted.
Prior work in patient cohorts has tended to examine the effects
of tVNS administered acutely and for short time periods (i.e.,
7 days). Therefore, future work should explore the magnitude
of the cardioprotective impacts of tVNS delivered over longer
time frames (e.g., 1, 2, 6 months, etc.). Of course, in order
to explore the contribution of placebo effects to improvements
associated with active stimulation, control conditions should be
carefully considered. This is an important point given that tVNS
is perceptible, therefore making it difficult to undertake double-
blinding in randomized control trials. Furthermore, due to the
recent controversy in the literature surrounding the innervation
of nerves in the external ear (Badran et al., 2018; Burger and
Verkuil, 2018; Mahadi et al., 2019), it is even more imperative
to determine a valid control for tVNS in cardiovascular research.
Control conditions have tended to comprise: (1) turning off
the device that delivers the stimulation without the participant’s
knowledge while positioned on the same part of the external ear
as used during active stimulation (Clancy et al., 2014; Antonino
et al., 2017; Bretherton et al., 2019) or (2) delivering active
stimulation to a part of the external ear thought not to be
innervated by the vagus nerve, e.g., the earlobe (Antonino et al.,
2017; Badran et al., 2018; Burger and Verkuil, 2018). Indeed,
active stimulation is associated with superior effects compared
to both sham stimulation techniques (Clancy et al., 2014;
Antonino et al., 2017; Badran et al., 2018; Burger and Verkuil,
2018; Bretherton et al., 2019). Perhaps future work should also
incorporate an arm in which participants receive conventional
MI treatments [e.g., β-blockers, NSAIDs, and angiotensin-
converting enzyme (ACE) inhibitors] in order to compare the
efficacy and safety of tVNS with current medical interventions.
It would also be prudent for future work to reflect on
which outcome measures would be of interest in cardiovascular
conditions. This is particularly crucial for clinicians if tVNS is
to be considered as a potential (adjunct) treatment modality.
Outcome measures could include infarct size, cardiac contractile,
diastolic and LV function, NYHA classification, mortality rate,
hospital and general practitioner (GP) admissions, length
of hospital stays, and medication consumption. As HF is
characterized by impairments in undertaking physical activity,
usually accompanied with reductions in quality of life, measures
which provide insight into the real-life consequences of the
condition would be valuable especially for patients. This could
include heart rate, oxygen uptake, carbon dioxide output,
ventilatory equivalent, respiratory rate, and anaerobic threshold
during a ramping treadmill exercise test. Questionnaires, such as
the Minnesota Living with Heart Failure questionnaire and the
Godin Leisure Time Exercise Questionnaire, could also be used
to provide subjective measures of health-related quality of life and
physical activity levels.
Due to the inflammatory responses inherent in MI, plasma
NE, pro-inflammatory cytokines, including TNFα, IL-1, and IL-6,
and anti-inflammatory cytokines such as IL-4 and IL-10 would be
worthwhile measuring. Indeed, these data could generate greater
understanding about what happens at the molecular level in
patients with MI when using tVNS (Stavrakis et al., 2017). As
autonomic balance is also impaired in patients with coronary
artery disease, measures of autonomic function such as HRV,
baroreceptor reflex sensitivity, and sympathetic nerve outflow
(derived by microneurography in the peroneal nerve) could also
be incorporated. Functional brain imaging techniques may also
be a useful addition, especially if a mechanistic account of tVNS
in an MI patient cohort is a key objective.
CONCLUSION
Despite inconclusive data from clinical trials, it is becoming
evident that electrical stimulation of the vagal nerve
can elicit cardioprotective effects against adverse cardiac
remodeling in animals. The cardioprotective effects of
VNS involve activation of the CAP which may reprogram
and rebalance the production of inflammatory cytokines
(Figure 2). However, recent findings suggest that other
neural pathways such as cervical spinal activation may
be involved in auricular tVNS (Mahadi et al., 2019). It
remains unknown how tVNS may activate the CAP in
cardiac macrophages similar to that shown in invasive
VNS. Combining molecular research with translational work
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investigating the cardioprotective effects of tVNS in patient
samples will aid with generating an account of how this
stimulation can improve the health of these patients, enabling
them to live a more fulfilling life.
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